This test is used to study and diagnose GI disorders such as dyspepsia, gastroesophageal reflux, peptic ulcer, Helicobacter Pylori infections, esophagitis, and irritable bowel syndrome, which are common conditions that also carry high health care costs. Despite being very common, these are highly underestimated and their actual incidence and prevalence is difficult to measure, although recent data suggests an increase in their frequency. Many of these conditions, if not adequately treated, can cause severe complications, potentially life-threatening.
This is the test of choice for screening for colon-rectum cancer, the most common GI tract tumor in Italy (51,900 cases in 2015, source: I numeri del cancro in Italia nel 2015, AIOM-AIRTUM, 2015) and Europe (471,000 cases in 2012, source: International Agency for Research on Cancer, WHO, 2012). The incidence is higher in men compared to women and in addition to family history and the presence of inflammatory bowel diseases, the main risk factors include diabetes, a diet low in fiber and high in saturated fats, a sedentary lifestyle, obesity, exposure to radiation, smoking, and alcohol abuse. The prognosis is relatively good compared to other gastrointestinal cancers. Colon-rectum cancer is the only kind of tumor for which a screening and periodical surveillance program for men has proved effective to reduce the mortality rate. For this reason, in prevention programs, all official health organizations recommend a colonoscopy for those over the age of 50.
Video capsule colonoscopy is a new endoscopy technique recently developed for painless and non-invasive diagnostic examination of the colon. This technique requires no sedation, radiation, or air insufflation. The capsule has two cameras that record at a speed of 4-35 images/second for approximately 10 hours. The color images are transmitted to a small videorecorder, similar to a portable CD player, which the patient wears around his/her waist. Ten hours after swallowing the capsule, the electronic support storing the footage is withdrawn and processed by a special software that compresses 10 hours of video in 60 minutes. The capsule is then passed by the patient naturally. The video capsule is the best solution to increase the performance of prevention tests as it is currently the only method of orally studying the colon.
EndoBarrier is a device that produces the same effects of intestinal bypass surgery.
Compared to other surgical approaches against obesity, this technique has several benefits. First of all, it’s less invasive as it does not involve surgery. Second, it’s reversible because once inserted the device can be removed at any time. Finally, it’s less expensive compared to traditional surgery for obesity.
EndoBarrier is introduced endoscopically inside the patient’s duodenal lumen in order to reduce food absorption and, possibly, modify the insulin production. EndoBarrier is a flexible waterproof tube anchored to the duodenal bulb with a removable anchor. Using an endoscope, doctors insert a sort of “protective liner” inside the patient’s mouth. Once in place, the liner creates a physical barrier between digested food and the intestinal wall. The EndoBarrier can stay in place for up to 12 months, after which it is removed.
Preliminary results of studies conducted in other EU countries are very encouraging, showing a loss of over 40% of excessive weight and, most of all, clinical remission of type 2 diabetes with a significant improvement of the conditions of patients undergoing this treatment.
According to the World Health Organization (WHO), diabetes will be the seventh leading cause of death in 2030. WHO estimates that, globally, 422 million adults were living with diabetes in 2014 (in Italy 8.5% of the population aged over 30 years had diabetes). These cases are mainly type 2 diabetes whose principal causes are obesity and lack of physical exercise. In 2014, globally more than 1 out of 3 adults was overweight and more than 1 out of 10 was obese (in Italy: 64% of adult population was overweight and 23.7% was obese). (Global Report on Diabetes – WHO, 2016).
To get an initial assessment about your suitability for the Endobarrier® procedure, fill out the form with your doctor’s help.
Our specialists will verify your suitability for the procedure and will call you back.
At the UPMC Institute for Health Chianciano Terme, we offer preventive medicine services for gastrointestinal, pancreatic, and cardiac diseases, metabolic syndrome, and diabetes. In other words, we take care of you.
The Italian division of the University of Pittsburgh Medical Center with facilities in Rome (UPMC San Pietro FBF, oncology radiotherapy and UPMC | Salvator Mundi International Hospital), Palermo (ISMETT IRCCS, organ transplants and highly specialized therapies and Ri.MED Foundation, research), Chianciano Terme (UPMC Institute for Health, preventive medicine and Medical Gym), Mirabella Eclano (UPMC Hillman Cancer Center at Villa Maria, oncology radiotherapy).
UPMC is an integrated global health enterprise headquartered in Pittsburgh, PA, USA. Its deep clinical, operational, and managerial expertise, combined with real-world experience, has made UPMC a leading health care provider in the United States. UPMC International shares clinical, technological, and managerial knowledge and expertise with partners across the globe customizing solutions to build the best possible health care for patients, close to home.